ImpriMed
A precision-oncology service that tests live cancer cells against drugs and uses clinical data to predict which treatments may work best for each patient.
$10MSeries A2 bridge
ParticipantHR
Han River Partners
Activity from announced rounds
Activity in this selectionlong-z-investments-3cb12046
- Rounds participated in
- 1
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $10M 1 disclosed · full round size, not this investor’s share